June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Investigating the genotype-phenotype relationships of patient specific PNPLA6 mutations
Author Affiliations & Notes
  • James Liu
    Medical Genetics and Ophthalmic Genomics Unit, National Eye Institute, Bethesda, Maryland, United States
  • Cara Lwin
    Medical Genetics and Ophthalmic Genomics Unit, National Eye Institute, Bethesda, Maryland, United States
    Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee, United States
  • Yi He
    Fermentation Facility, Biochemistry and Biophysics Center, National Heart Lung and Blood Institute, Bethesda, Maryland, United States
  • Gavin Arno
    UCL Institute of Ophthalmology, University College London, London, London, United Kingdom
    Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
  • Anthony T Moore
    Joint Library of Ophthalmology Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, London, United Kingdom
    Ophthalmology Department, University of California San Francisco, San Francisco, California, United States
  • Andrew Webster
    UCL Institute of Ophthalmology, University College London, London, London, United Kingdom
    Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
  • Laryssa A Huryn
    Ophthalmic Genetics and Visual Function Branch, National Eye Institute, Bethesda, Maryland, United States
  • Bin Guan
    Medical Genetics and Ophthalmic Genomics Unit, National Eye Institute, Bethesda, Maryland, United States
  • Robert B Hufnagel
    Medical Genetics and Ophthalmic Genomics Unit, National Eye Institute, Bethesda, Maryland, United States
    Ophthalmic Genetics and Visual Function Branch, National Eye Institute, Bethesda, Maryland, United States
  • Footnotes
    Commercial Relationships   James Liu, None; Cara Lwin, None; Yi He, None; Gavin Arno, None; Anthony Moore, None; Andrew Webster, None; Laryssa Huryn, None; Bin Guan, None; Robert Hufnagel, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 1519. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      James Liu, Cara Lwin, Yi He, Gavin Arno, Anthony T Moore, Andrew Webster, Laryssa A Huryn, Bin Guan, Robert B Hufnagel; Investigating the genotype-phenotype relationships of patient specific PNPLA6 mutations. Invest. Ophthalmol. Vis. Sci. 2021;62(8):1519.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Pathogenic variants in the PNPLA6 gene cause a broad spectrum of neurological disorders such as spastic paraplegia type 39 (SPG39), Gordon-Holmes syndrome (GHS), Boucher-Neuhauser syndrome (BNHS), Laurence-Moon syndrome (LMS), and Oliver-McFarlane syndrome (OMS). PNPLA6 encodes Neuropathy Target Esterase (NTE), yet it’s unclear why NTE enzymatic dysfunction causes early childhood onset retinopathy in a subset of patients. Here, we investigate the relationship between PNPLA6 genotype-associated enzymatic activity and risk of retinal degeneration.

Methods : PNPLA6 variants were detected by NGS, sanger sequencing, and digital droplet PCR. Clinical meta-analysis was performed on 133 previously reported patients by literature search (PubMed, 2008-2020). Statistical analysis was performed in Prism. DNA constructs containing full length NTE underwent site directed mutagenesis to produce the patient specific proteins. NTE activity was determined as previously published (PMID:12791540). Intronic variants were assessed for splice alterations by minigene assay.

Results : Biallelic pathogenic PNPLA6 variants were detected in ten patients with clinical diagnosis of SPG39, BNHS or OMS, including 7 novel variants. Clinical meta-analysis of these and 75 previously reported genotyped patients indicated significant differences in ophthalmic and endocrinologic symptom onset between clinical diagnosis categories. Intriguingly, patients with early onset retinopathy were not more likely to harbor truncating variants, and no differences in disease onset or tissues affected were found between those with and without truncating variants. To examine effects of missense alleles on phenotype, we measured activity in 17 variants observed in two or more patients with the same clinical diagnosis. Residual esterase activity of recurrent missense variants observed in patients with retinopathy was significantly lower compared to those without reported visual symptoms.

Conclusions : Molecular determinants of retinal disease onset is different among clinical diagnoses of PNPLA6-opathies. Enzyme activity of recurrent disease-associate missense variants indicates a relationship between enzymatic activity and likelihood of retinopathy, implicating missense variants as drivers of tissue-specific disease onset. This supports a genotype:activity:phenotype relationship among PNPLA6-opathies that may be valuable for both diagnosis and prognosis.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×